
Janssen's supply of Ebola vaccines is running low, so the pharmaceutical group has ordered more from Bavarian Nordic.
This is good news for the Danish biotech firm, which will receive just over DKK 91 million (USD 12.8 million), but Financial Director Henrik Juuel explains that this isn't something the firm expects to happen regularly.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app